Review of the Use of Antisense Oligonucleotides as Therapy for Huntington's Disease
DOI:
https://doi.org/10.56294/sctconf2024923Keywords:
Antisense Oligonucleotides, Huntington's Disease, Mutated Huntingtin, Wild-Type Huntingtin, Modulation, Clinical TrialsAbstract
Introduction: Huntington's disease is a neurodegenerative disorder characterized by the progressive degeneration of nerve cells in the brain, and whose current treatment focuses on the control of symptoms, which is why in recent years several therapies have been evaluated, including Antisense oligonucleotides a promising strategy, thanks to their ability to modulate the expression of the mutated huntingtin protein.
Methods: a bibliographic search was carried out using the PRISMA methodology in databases such as PubMed, limited to documents in English published during the last 5 years, using keywords such as "Huntington's Disease", "Antisense Oligonucleotides", "Treatment" “Tominersen”, selecting only documents such as original articles, bibliographic reviews and clinical trial reports related to the use of Antisense Oligonucleotides as therapy for Huntington's Disease.
Results: 150 articles were collected and analyzed, of which 30 documents were excluded due to their age and 40 due to lack of access and quality of information, leaving a total of 80 articles to which inclusion criteria were applied, selecting 25 articles for completion. of this literature review on the use of antisense oligonucleotides in Huntington's disease
Conclusion: antisense oligonucleotides show great therapeutic potential for Huntington's disease by directly attacking the underlying cause of the disease, mutated huntingtin. However, significant challenges still remain, which is why better research is needed to ensure efficacy. and safety of this therapy in the long term
References
1. Ferguson MW, Kennedy CJ, Palpagama TH, Waldvogel HJ, Faull RLM, Kwakowsky A. Current and Possible Future Therapeutic Options for Huntington’s Disease. Journal of Central Nervous System Disease. 2022.
2. Jiang A, Handley RR, Lehnert K, Snell RG. From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington’s Disease Research. International Journal of Molecular Sciences. 2023.
3. Kim A, Lalonde K, Truesdell A, Welter PG, Brocardo PS, Rosenstock TR, Gil‐mohapel J. New avenues for the treatment of huntington’s disease. International Journal of Molecular Sciences. 2021.
4. Jurcau A, Simion A, Jurcau MC. Emerging antibody-based therapies for Huntington’s disease: current status and perspectives for future development. Expert Rev Neurother. 2024 Feb 7;1–14.
5. Rook ME, Southwell AL. Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic. BioDrugs. 2022;36(2).
6. van Lonkhuizen PJC, Frank W, Heemskerk AW, van Duijn E, de Bot ST, Mühlbäck A, Landwehrmeyer GB, Chavannes NH, Meijer E, Chavannes NH, de Bot ST, van Lonkhuizen PJC, Landwehrmeyer GB, Steck F, Klempíř J, Konvalinková R, Bezuchová E, Dolečková K, Klempířová O, Roth J, Ulmanová O, Squitieri F, Maffi S, Scaricamazza E, Migliore S, Di Giorgio C, D’Alessio B, Casella M, Hoblyn J, Thangaramanujam M, Burke T, O’Malley E, McKenna S, McKenna I, Thorpe J, Coffey A, Moldovan R, Foley P, Kerr J. Quality of life, health-related quality of life, and associated factors in Huntington’s disease: a systematic review. Journal of Neurology. 2023.
7. Shaw E, Mayer M, Ekwaru P, McMullen S, Graves E, Wu JW, Budd N, Maturi B, Cowling T, Mestre TA. Disease Burden of Huntington’s Disease (HD) on People Living with HD and Care Partners in Canada. J Huntingtons Dis. 2022;11(2).
8. Alkanli SS, Alkanli N, Ay A, Albeniz I. CRISPR/Cas9 Mediated Therapeutic Approach in Huntington’s Disease. Molecular Neurobiology. 2023.
9. Gonzalez Rojas N, Cesarini ME, Peker G, Da Prat GA, Etcheverry JL, Gatto EM. Review of Huntington’s Disease: From Basics to Advances in Diagnosis and Treatment. J Neurol Res. Elmer Press, Inc.; 2022 Oct;12(3):93–113.
10. Monine M, Norris D, Wang Y, Nestorov I. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration. J Pharmacokinet Pharmacodyn. 2021;48(5).
11. Egli M, Manoharan M. Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Res. 2023;51(6).
12. Krishnan A V., Mishra D. Antisense Oligonucleotides: A Unique Treatment Approach. Indian Pediatrics. 2020.
13. Kilanowska A, Studzińska S. In vivo and in vitro studies of antisense oligonucleotides–a review. RSC Advances. 2020.
14. Shadid M, Badawi M, Abulrob A. Antisense oligonucleotides: absorption, distribution, metabolism, and excretion. Expert Opinion on Drug Metabolism and Toxicology. 2021.
15. Takakusa H, Iwazaki N, Nishikawa M, Yoshida T, Obika S, Inoue T. Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs. Nucleic Acid Therapeutics. 2023.
16. Lauffer MC, van Roon-Mom W, Aartsma-Rus A. Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders. Communications Medicine [Internet]. 2024 Jan 5;4(1):6. Available from: https://www.nature.com/articles/s43856-023-00419-1
17. Crooke ST, Baker BF, Crooke RM, Liang X hai. Antisense technology: an overview and prospectus. Nature Reviews Drug Discovery. 2021.
18. Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nature Reviews Drug Discovery. 2020.
19. Dhuri K, Bechtold C, Quijano E, Pham H, Gupta A, Vikram A, Bahal R. Antisense oligonucleotides: An emerging area in drug discovery and development. Journal of Clinical Medicine. 2020.
20. Gopi C, Dhanaraju MD, Dhanaraju K. Antisense oligonucleotides: recent progress in the treatment of various diseases. Beni-Suef University Journal of Basic and Applied Sciences. Springer Science and Business Media Deutschland GmbH; 2022.
21. Helm J, Schöls L, Hauser S. Towards Personalized Allele-Specific Antisense Oligonucleotide Therapies for Toxic Gain-of-Function Neurodegenerative Diseases. Pharmaceutics. MDPI; 2022.
22. Scoles DR, Minikel E V., Pulst SM. Antisense oligonucleotides: A primer. Neurol Genet. 2019;5(2).
23. Hammond SM, Aartsma‐Rus A, Alves S, Borgos SE, Buijsen RAM, Collin RWJ, Covello G, Denti MA, Desviat LR, Echevarría L, Foged C, Gaina G, Garanto A, Goyenvalle AT, Guzowska M, Holodnuka I, Jones DR, Krause S, Lehto T, Montolio M, Van Roon‐Mom W, Arechavala‐Gomeza V. Delivery of oligonucleotide‐based therapeutics: challenges and opportunities. EMBO Mol Med. 2021;13(4).
24. Ramasamy T, Ruttala HB, Munusamy S, Chakraborty N, Kim JO. Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics. Journal of Controlled Release. 2022;352.
25. Estevez-Fraga C, Tabrizi SJ, Wild EJ. Huntington’s Disease Clinical Trials Corner: August 2023. J Huntingtons Dis. 2023;12(2).
Published
Issue
Section
License
Copyright (c) 2024 Ariel Solis Chiriboga, Alberto Bustillos (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
